KROS CIK: 1664710

Keros Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−62.1
FY22:
−70.1
FY23:
−125
FY24:
−161
FY25:
108
Change from FY21 to FY25
millions USD
FY21:
−1.02
FY22:
−1.24
FY23:
−2.46
FY24:
−1.93
FY25:
−1.55
Change from FY21 to FY25
millions USD
FY21:
28.6
FY22:
120
FY23:
179
FY24:
392
FY25:
−378
millions USD
FY21:
−34.6
FY22:
49.0
FY23:
52.0
FY24:
229
FY25:
−273
(positive)
Change from FY21 to FY25
millions USD
FY21:
−63.2
FY22:
−71.3
FY23:
−127
FY24:
−163
FY25:
106

All amounts in millions USD Data source:SEC EDGAR